Stellate Ganglion Block to Treat Long C… | Clinical Trial

Key information

Conditions

Long COVID Anosmia Autonomic Nervous System Diseases Behavior Behavioral Symptoms Brain Fog COVID-19 Chronic Disease Coronaviridae Infections Coronavirus Infections Cough Disease Attributes Dizziness Dysautonomia Dysgeusia Dyspnea Fatigue Fatigue Post Viral Infections Long Covid19 Lung Diseases Menstrual Cycle Abnormal Mental Fatigue Muscle Pain Muscular Diseases Musculoskeletal Diseases Musculoskeletal Pain Myalgia Nervous System Diseases Neurologic Manifestations Neuromuscular Diseases Nidovirales Infections Olfaction Disorders Pain Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral Post Acute COVID-19 Syndrome Post-Acute COVID-19 Syndrome Post-COVID-19 Syndrome Post-Infectious Disorders RNA Virus Infections Respiration Disorders Respiratory Tract Diseases Respiratory Tract Infections Sensation Disorders Shortness of Breath Signs and Symptoms Signs and Symptoms, Respiratory Taste Disorders Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Metamorphosis LTD

Cañon City, Colorado, 81212, United States

About this study

We evaluated the treatment results of 41 patients (18 male and 23 female) aged between 18 and 89, who received Stellate Ganglion Block (SGB) with Ultrasound guidance for Long COVID-19 Syndrome. The patients were from the United States and received treatment at our Colorado clinics during the period of September to December 2022.Those who responded to our post-procedure follow-up calls were included in the study population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

People who scheduled themselves for a SGB in our clinics in Colorado.

-

Exclusion criteria

Stellate Ganglion Block Contraindications

-

Treatment and study plan

Stellate ganglion block

Procedure

Ultrasound guided block of the Stellate Ganglion with local anesthetics.

Other names: SGB

Primary outcomes

Symptom Response

Time frame: 3 months

Evaluation of the symptoms response to the Stellate Ganglion Block

Sponsors and collaborators

Lead sponsor

Metamorphosis LTD

Other

Registry information

Official study title

Stellate Ganglion Block to Treat Long COVID-19 Syndrome, A 41 Patient Retrospective Cohort Study

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: Apr 13, 2023
Registry last updated: Apr 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed